Ginkgo Bioworks (NYSE:DNA) vs. Integrated Diagnostics (OTCMKTS:IDGXF) Critical Review

Integrated Diagnostics (OTCMKTS:IDGXF) and Ginkgo Bioworks (NYSE:DNA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Integrated Diagnostics and Ginkgo Bioworks, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated Diagnostics	0	0	0	0	0.00
Ginkgo Bioworks	2	1	0	0	1.33

Ginkgo Bioworks has a consensus price target of $7.00, suggesting a potential upside of 2.99%. Given Ginkgo Bioworks’ stronger consensus rating and higher probable upside, analysts plainly believe Ginkgo Bioworks is more favorable than Integrated Diagnostics.

Valuation and Earnings

This table compares Integrated Diagnostics and Ginkgo Bioworks”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated Diagnostics	N/A	N/A	N/A	N/A	N/A
Ginkgo Bioworks	$170.15 million	2.69	-$312.76 million	($5.01)	-1.36

Integrated Diagnostics has higher earnings, but lower revenue than Ginkgo Bioworks.

Insider & Institutional Ownership

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Integrated Diagnostics and Ginkgo Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integrated Diagnostics	N/A	N/A	N/A
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Summary

Ginkgo Bioworks beats Integrated Diagnostics on 5 of the 8 factors compared between the two stocks.

About Integrated Diagnostics

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, including positron emission tomography computed tomography (PET-CT), magnetic resonance imaging (MRI), computed tomography (CT), mammography, ultrasound, x-ray, electromyography (EMG), electroencephalography, electroencephalogram (EEG), and electrocardiogram (ECG), as well as operates cath lab facilities. It operates in Egypt, Sudan, Jordan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.